Paricalcitol Versus Calcitriol for the Management of Renocardiac Syndrome in Renal Transplant Patients

Ural State Medical University

Status and phase: Completed; Phase 4

Conditions: Chronic Allograft Nephropathy; Cardiorenal Syndrome

Treatments: Drug: Paricalcitol; Drug: Cholecalciferol; Drug: Calcitriol; Dietary Supplement: Supplemental

Study type: Interventional

Funder types: Other

Identifiers

NCT01265615

VDCRS03

Details and patient eligibility

About

We hypothesize that paricalcitol and calcitriol in dose-dependent manner are effective for the management of chronic allograft dysfunction (CAD), protection and repair of kidney and heart, management of chronic renocardiac syndrome (CRS). We assume that paricalcitol can have some advantages if compare with calcitriol or cholecalciferol due to absence of calcemic and phosphatemic complications alongside with great beneficial potential.

Full description

Paricalcitol and calcitriol are identically effective for the management of chronic allograft dysfunction (CAD), protection and repair of kidney and heart, management of chronic renocardiac syndrome (CRS). Vitamin D can reduce progression of CAD. Activation of VDR in proximal part of nephron leads to rapid non-genomic beneficial effects with urgent multilevel protection of the most functionally important portion of kidney. Rising expression of VDR in distal portions of nephron stimulates slows genomic effects with some local repair responses.

Hormone D may stimulate recruitment and activity of the different origin stem-progenitor cells (SPCs) with beneficial effects on different stages of regeneration by force of para- and autocrine activity. SPCs are revealing mostly in interstitium and among fibroblast-like cells. Vitamin D did not confirm efficacy as a tool for management of mesenchymal stem cells (MSCs) in human however it needs more research experimental evidences due to multifactorial influence on SPCs in human being including immunosuppressive and bone-marrow-related effects of cyclosporine in kidney transplant (Tx) patients. Paricalcitol and calcitriol can slow down migration and infiltration of MSC into interstitium and vessel wall. The side population of mature and SPCs (first of all, with bone-marrow and mesenchymal phenotype) is the most metabolically and functionally active portion of cells with high sensitivity to vitamin D receptor (VDR) activation that responsible for repair of tissue.

The most optimal scheme of treatment with vitamin D in patients with CAD and CRS is an administration of paricalcitol with dose 2-4 μg daily and supplemental intake of vitamin D including special diet, multivitamins, and others with optimal dose until 1800 international units (IU) but excluding insolation as a factor of skin carcinoma. High-dose medicinal intake of calcitriol (until 6 mcg and higher) showed relatively high efficacy but rather excessive level of complications mediated with mineral metabolism.

Paricalcitol and calcitriol may significantly improve contractility of myocardium and reduce cardiovascular risk, heart failure (HF) and hypertension with some beneficial effects on cardiorenal axis and renin-angiotensin-aldosterone system.

Enrollment: 109 patients

Sex: Male

Ages: 40 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age 40-75
• Male
• History of chronic kidney disease and cardiorenal syndrome
• Written informed consent

Exclusion criteria

• Female
• Acute illness
• Life-threat competitive illness
• Mental disorders
• Endocrinologic diseases (including diabetes mellitus, hyperparathyroidism, and other thyroid disorders)
• Need for dialyses
• Hypercalcemia
• Concomitant use of hormone or cytokine medication
• Participation to any drug-investigation during the previous 60 days as checked with VIP check

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

109 participants in 4 patient groups

Paricalcitol treatment

Active Comparator group

Description:

6-8 μg daily per os (orally) without special diet

Treatment:

Drug: Paricalcitol

Calcitriol treatment

Active Comparator group

Description:

2-4 μg daily orally under with dietary restrictions of vitamin D

Treatment:

Drug: Calcitriol

Cholecalciferol

Active Comparator group

Description:

alendronate sodium/ cholecalciferol capsules with recommended daily allowance equals 1200-2400 IU per day

Treatment:

Drug: Cholecalciferol

Supplemental

Other group

Description:

intake of cholecalciferol in food and multivitamins, less than 400-900 IU per day

Treatment:

Dietary Supplement: Supplemental